Myokardia (MYOK) Stock Price Down 6.7%

Shares of Myokardia Inc (NASDAQ:MYOK) traded down 6.7% during trading on Wednesday . The stock traded as low as $33.20 and last traded at $33.20. 714,851 shares changed hands during trading, an increase of 125% from the average session volume of 318,275 shares. The stock had previously closed at $35.60.

Several analysts recently commented on the company. BMO Capital Markets reiterated a “buy” rating and set a $45.00 price target (up from $32.00) on shares of Myokardia in a research report on Tuesday, August 8th. Zacks Investment Research upgraded Myokardia from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. ValuEngine cut Myokardia from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Wedbush restated an “outperform” rating and issued a $51.00 target price on shares of Myokardia in a report on Wednesday, September 20th. Finally, TheStreet cut Myokardia from a “c” rating to a “d+” rating in a report on Friday, November 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $55.00.

Myokardia (NASDAQ:MYOK) last released its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.42) EPS for the quarter, meeting analysts’ consensus estimates of ($0.42). The business had revenue of $5.63 million for the quarter, compared to the consensus estimate of $6.10 million. Myokardia had a negative return on equity of 14.92% and a negative net margin of 53.49%. The business’s revenue for the quarter was up 58.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.35) EPS. analysts expect that Myokardia Inc will post -1.62 EPS for the current year.

In other news, Director Kevin P. Starr sold 75,313 shares of the firm’s stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $40.28, for a total value of $3,033,607.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Anastasios Gianakakos sold 4,300 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $40.23, for a total value of $172,989.00. Following the completion of the sale, the chief executive officer now directly owns 513,417 shares of the company’s stock, valued at $20,654,765.91. The disclosure for this sale can be found here. Insiders sold a total of 1,709,213 shares of company stock worth $72,493,582 over the last quarter. Company insiders own 33.40% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN increased its position in Myokardia by 2.5% during the second quarter. Wells Fargo & Company MN now owns 18,539 shares of the biotechnology company’s stock worth $243,000 after buying an additional 455 shares in the last quarter. American International Group Inc. grew its position in shares of Myokardia by 18.8% in the third quarter. American International Group Inc. now owns 12,735 shares of the biotechnology company’s stock valued at $546,000 after purchasing an additional 2,018 shares during the period. Fiduciary Trust Co. grew its position in shares of Myokardia by 7.2% in the second quarter. Fiduciary Trust Co. now owns 30,612 shares of the biotechnology company’s stock valued at $401,000 after purchasing an additional 2,058 shares during the period. Rhumbline Advisers grew its position in shares of Myokardia by 12.4% in the third quarter. Rhumbline Advisers now owns 20,788 shares of the biotechnology company’s stock valued at $891,000 after purchasing an additional 2,299 shares during the period. Finally, Schwab Charles Investment Management Inc. grew its position in shares of Myokardia by 5.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 43,680 shares of the biotechnology company’s stock valued at $575,000 after purchasing an additional 2,394 shares during the period. 63.61% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Myokardia (MYOK) Stock Price Down 6.7%” was posted by Stock Observer and is the property of of Stock Observer. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.thestockobserver.com/2017/12/06/myokardia-myok-stock-price-down-6-7.html.

Myokardia Company Profile

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Receive News & Ratings for Myokardia Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply